Log in

Relevant bibliographies by topics / Metronomica / Journal articles

To see the other types of publications on this topic, follow the link: Metronomica.

Journal articles on the topic 'Metronomica'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Metronomica.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Orlandi, Armando, Elena Iattoni, Carmela Di Dio, and Maria Alessandra Calegari. "Efficacia duratura e ottima tollerabilità di lapatinib associato a capecitabina metronomica in due pazienti con carcinoma mammario HER2-positivo." AboutOpen 3, no. 1 (2017): 112–16. http://dx.doi.org/10.19156/abtpn.2017.0026.

Full text

Abstract:

L’utilizzo di lapatinib in combinazione con capecitabina è associato in alcune pazienti a tossicità gastrointestinale e cutanea, che ne compromette la regolare assunzione limitando l’utilizzo di un’efficace schedula terapeutica nel carcinoma metastatico della mammella HER2-positivo, refrattario al trattamento con trastuzumab. I due casi clinici presentati mostrano il buon profilo di tossicità e l’efficacia della combinazione lapatinib (1250 mg/die) + capecitabina metronomica (500 mg 3 volte/die) (Oncology).

APA, Harvard, Vancouver, ISO, and other styles

2

Arvat, Emanuela. "Impiego della chemioterapia metronomica in pazienti con carcinoma surrenalico metastatico sottoposti a multipli trattamenti precedenti." L'Endocrinologo 15, no. 5 (2014): 240. http://dx.doi.org/10.1007/s40619-014-0074-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Revon-Rivière, Gabriel, Shripad Banavali, Laila Heississen, et al. "Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists." Journal of Global Oncology, no. 5 (December 2019): 1–8. http://dx.doi.org/10.1200/jgo.18.00244.

Full text

Abstract:

PURPOSE Low- and middle-income countries (LMICs) experience the burden of 80% of new childhood cancer cases worldwide, with cure rates as low as 10% in some countries. Metronomics combines frequent administrations of low-dose chemotherapy with drug repurposing, which consists of using already-approved drugs for new medical applications. With wide availability, limited costs, and little infrastructure needs, metronomics can be part of constraint-adapted regimens in these resource-limited settings—with the understanding that metronomics shall not be a substitute for standard treatments when avai

APA, Harvard, Vancouver, ISO, and other styles

4

Svoboda, Tomáš. "Metronomic chemotherapy in breast cancer." Onkologie 10, no. 4 (2016): 161–65. http://dx.doi.org/10.36290/xon.2016.035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Muraro, Elena, Lorenzo Vinante, Elisabetta Fratta, et al. "Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors." Cancers 15, no. 9 (2023): 2471. http://dx.doi.org/10.3390/cancers15092471.

Full text

Abstract:

Increasing evidence pinpoints metronomic chemotherapy, a frequent and low dose drug administration with no prolonged drug-free intervals, as a potential tool to fight certain types of cancers. The primary identified targets of metronomic chemotherapy were the tumor endothelial cells involved in angiogenesis. After this, metronomic chemotherapy has been shown to efficiently target the heterogeneous population of tumor cells and, more importantly, elicit the innate and adaptive immune system reverting the “cold” to ”hot” tumor immunologic phenotype. Although metronomic chemotherapy is primarily

APA, Harvard, Vancouver, ISO, and other styles

6

Teixeira, N. C. T., A. P. C. V. Bicalho, A. V. Vasconcelos, R. S. Horta, R. M. C. Cunha, and G. E. Lavalle. "Ciclooxygenase inhibitor and metronomic chemotherapy association for the treatment of metastatic anal sac carcinoma in dog: case report." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 68, no. 4 (2016): 913–18. http://dx.doi.org/10.1590/1678-4162-8439.

Full text

Abstract:

ABSTRACT Metronomic chemotherapy consists of an anticancer modality treatment. It is applicable in patients at an advanced stage, with the objective of increasing overall survival. The aim of this study was to report an anal sac apocrine carcinoma case in a dog with lymph node metastasis treated with metronomic chemotherapy sequential to surgery and conventional chemotherapy using gemcitabine and carboplatin. Metronomic chemotherapy was associated with cyclooxygenase-2 (COX-2) inhibitors, due to strong tumor COX-2 immunohistochemistry expression. Metronomic chemotherapy was initiated with cycl

APA, Harvard, Vancouver, ISO, and other styles

7

Olovnikov, Alexey M. "Planetary Metronome as a Regulator of Lifespan and Aging Rate: The Metronomic Hypothesis." Biochemistry (Moscow) 87, no. 12-13 (2022): 1640–50. http://dx.doi.org/10.1134/s0006297922120197.

Full text

Abstract:

Abstract A metronomic mechanism for the duration control of ontogenetic cycle periods of an animal is proposed. The components of the proposed metronomic system include the ventricular system of the brain, planet Earth as a generator of metronomic signals, and temporal DNA (tDNA) as a substrate that is epigenetically marked to measure elapsed time of ontogenesis. The metronomic system generates repetitive signals in the form of hydrodynamic disturbances in the cerebrospinal fluid (CSF). The metronomic effect arises due to the superposition of two processes – the near-wall unidirectional flow o

APA, Harvard, Vancouver, ISO, and other styles

8

Su, Nai-Wen, and Yu-Jen Chen. "Metronomic Therapy in Oral Squamous Cell Carcinoma." Journal of Clinical Medicine 10, no. 13 (2021): 2818. http://dx.doi.org/10.3390/jcm10132818.

Full text

Abstract:

Metronomic therapy is characterized by drug administration in a low-dose, repeated, and regular manner without prolonged drug-free interval. The two main anticancer mechanisms of metronomic therapy are antiangiogenesis and immunomodulation, which have been demonstrated in several delicate in vitro and in vivo experiments. In contrast to the traditional maximum tolerated dose (MTD) dosing of chemotherapy, metronomic therapy possesses comparative efficacy but greatlydecreases the incidence and severity of treatment side-effects. Clinical trials of metronomic anticancer treatment have revealed pr

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Mu, Chen Chen, Feng Su, Zhiguo Huang, Xiangmin Li та Xiaogang Li. "Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts". Technology in Cancer Research & Treatment 16, № 5 (2016): 609–19. http://dx.doi.org/10.1177/1533034616665720.

Full text

Abstract:

Low-dose metronomic chemotherapy represents a new strategy for solid tumor treatments with a strong antiangiogenic activity and few side effects. However, low-dose metronomic therapy alone is not always as effective as traditional chemotherapy on eradication of tumor. On the contrary, low-dose metronomic in some cases could stimulate tumor growth due to hypoxia of tumor cells induced during therapy. Our study aimed to investigate whether knockdown of hypoxia-inducible factor-1α expression in tumor cell could facilitate low-dose metronomic therapy with paclitaxel for human colon cancer. Human c

APA, Harvard, Vancouver, ISO, and other styles

10

Sun, Xiaofei, Zijun Zhen, Ying Guo, et al. "Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies." Cancers 13, no. 14 (2021): 3494. http://dx.doi.org/10.3390/cancers13143494.

Full text

Abstract:

Despite aggressive treatment, the prognosis of high-risk NB patients is still poor. This retrospective study investigated the benefits of metronomic maintenance treatment (MT) in high-risk NB patients without ASCT or GD2 antibody therapy. Patients aged ≤ 21 years with newly diagnosed high-risk NB were included. Patients with complete/very good partial remission (CR/VGPR/PR) to conventional treatment received, or not, oral metronomic MT for 1 year. Two hundred and seventeen high-risk NB patients were enrolled. One hundred and eighty-five (85%) had a CR/VGPR/PR to conventional treatment, of the

APA, Harvard, Vancouver, ISO, and other styles

11

Patwardhan, A. R., J. M. Evans, E. N. Bruce, D. L. Eckberg, and C. F. Knapp. "Voluntary control of breathing does not alter vagal modulation of heart rate." Journal of Applied Physiology 78, no. 6 (1995): 2087–94. http://dx.doi.org/10.1152/jappl.1995.78.6.2087.

Full text

Abstract:

Variations in respiratory pattern influence the heart rate spectrum. It has been suggested, hence, that metronomic respiration should be used to correctly assess vagal modulation of heart rate by using spectral analysis. On the other hand, breathing to a metronome has been reported to increase heart rate spectral power in the high- or respiratory frequency region; this finding has led to the suggestion that metronomic respiration enhances vagal tone or alters vagal modulation of heart rate. To investigate whether metronomic breathing complicates the interpretation of heart rate spectra by alte

APA, Harvard, Vancouver, ISO, and other styles

12

Phillips, Cameron, Giulio Francia, Robert S. Kerbel, and Urban Emmenegger. "Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial." Journal of Clinical Oncology 37, no. 7_suppl (2019): TPS346. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.tps346.

Full text

Abstract:

TPS346 Background: There is a continued need to identify novel targets for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). DNA damage repair (DDR) aberrations are emerging as such a target: 20%-30% of mCRPCs harbor DDR gene aberrations, rendering tumors particularly sensitive to DNA damaging agents and poly ADP-ribose polymerase inhibitor (PARPi) therapy. 88% of men with DDR deficient mCRPC responded to the PARPi olaparib in a phase II trial, whereas in unselected mCRPC patients the metronomic use of the DNA damaging agent cyclophosphamide (CPA) resulted in response

APA, Harvard, Vancouver, ISO, and other styles

13

Sul, J., K. S. Panageas, A. B. Lassman, et al. "A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 2031. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.2031.

Full text

Abstract:

2031 Background: Metronomic and dose dense scheduling are alternatives to conventional TMZ regimens to overcome drug resistance in part by depleting O-6 methylguanine-DNA methyltransferase (MGMT). Furthermore, metronomic TMZ may inhibit endothelial recovery and act as an anti-angiogenic therapy; dose dense TMZ increases the intensity of drug delivery. Objective: To determine the overall (OS) and progression free survival (PFS) of patients with newly diagnosed GBM treated with concurrent TMZ and RT followed by dose dense or metronomic TMZ and maintenance cis-retinoic acid. Methods: Patients wit

APA, Harvard, Vancouver, ISO, and other styles

14

Cazzaniga, Marina Elena, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva, and Maria Grazia Cerrito. "Metronomic Chemotherapy." Cancers 13, no. 9 (2021): 2236. http://dx.doi.org/10.3390/cancers13092236.

Full text

Abstract:

Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi-target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as

APA, Harvard, Vancouver, ISO, and other styles

15

Mutsaers, Anthony J. "Metronomic Chemotherapy." Topics in Companion Animal Medicine 24, no. 3 (2009): 137–43. http://dx.doi.org/10.1053/j.tcam.2009.03.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kamen, Barton A. "Metronomic Therapy." Journal of Pediatric Hematology/Oncology 27, no. 11 (2005): 571–72. http://dx.doi.org/10.1097/01.mph.0000192148.90120.15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Maiti, Rituparna. "Metronomic chemotherapy." Journal of Pharmacology and Pharmacotherapeutics 5, no. 3 (2014): 186. http://dx.doi.org/10.4103/0976-500x.136098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Vergnenegre, Alain, Isabelle Monnet, Acya Bizieux, et al. "Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC‡ 04-2017)." Future Oncology 16, no. 4 (2020): 5–10. http://dx.doi.org/10.2217/fon-2019-0730.

Full text

Abstract:

Metronomic chemotherapy is defined as frequent low-dose administration without prolonged drug-free breaks. Combining immune-checkpoint inhibitors and metronomic chemotherapy is a new approach to improve responses and delay onset of resistance to immune-checkpoint inhibitors. This multicenter, Phase II, open-label, single-arm study was designed to assess the safety and efficacy of metronomic oral vinorelbine in combination with immune-checkpoint inhibitors in advanced non-small-cell lung cancers progressing after first-line platinum-based chemotherapy. The recommended metronomic oral vinorelbin

APA, Harvard, Vancouver, ISO, and other styles

19

Ma, Fei, Xinlan Liu, Yanxia Shi, et al. "Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis." Cancer Research 82, no. 4_Supplement (2022): P1–16–02—P1–16–02. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-16-02.

Full text

Abstract:

Abstract Background: Metronomic chemotherapy, defined as frequent administration of. chemotherapeutic agents at a non-toxic dose without extended rest periods, can overcome drug resistance and achieve disease control with reduced toxicity compared to conventional chemotherapy in maximum tolerated dose by shifting the therapeutic target from tumor cells to tumor endothelial cells. Some of the previous studies of oral vinorelbine have shown good data in efficacy and safety in advanced breast cancer. Methods: The multicenter, open-label, non-inferiority, randomized phase 2 study (NCT03854617) aim

APA, Harvard, Vancouver, ISO, and other styles

20

Mutlu, H., H. Bozcuk, M. Ozdogan, et al. "Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer patients." Journal of Clinical Oncology 27, no. 15_suppl (2009): 1082. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1082.

Full text

Abstract:

1082 Background: To assess the efficacy of semi-metronomic regimen metronomic cyclophosphomide with oral etoposide in heavily treated patients with metastatic breast cancer. Methods: Consecutive metastatic breast cancer (MBC) patients predominantly refractory to antracyclines, taxanes, and antimetabolites receiving semi-metronomic regimen of metronomic cyclophosphomide with oral etoposide were evaluated for clinical efficacy and toxicity. This novel regimen comprised of continuous oral cyclophosphomide 50 mg/day, and oral etoposide given as 2 x 50 mg/day for 5 days. Results: A total of 42 MBC

APA, Harvard, Vancouver, ISO, and other styles

21

Ma, Jun, Yu-Pei Chen, Ying Sun, et al. "Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial." Journal of Clinical Oncology 39, no. 15_suppl (2021): 6003. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.6003.

Full text

Abstract:

6003 Background: Patients suffering from locoregionally advanced nasopharyngeal carcinoma (NPC) commonly develop disease recurrence, despite a high rate of complete clinical remission after standard of care (concurrent cisplatin-radiotherapy, with or without induction chemotherapy). The benefit of additional adjuvant chemotherapy remains unclear. Methods: Patients with high-risk locoregionally advanced NPC (stage III to IVA, excluding T3-4N0 and T3N1), and with no locoregional disease or distant metastasis after definitive chemoradiotherapy, were eligible. They were randomly assigned (1:1) wit

APA, Harvard, Vancouver, ISO, and other styles

22

Simsek, Cem, Ece Esin, and Suayib Yalcin. "Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience." Journal of Oncology 2019 (March 20, 2019): 1–31. http://dx.doi.org/10.1155/2019/5483791.

Full text

Abstract:

Metronomic chemotherapy, continuous and dose-dense administration of chemotherapeutic drugs with lowered doses, is being evaluated for substituting, augmenting, or appending conventional maximum tolerated dose regimens, with preclinical and clinical studies for the past few decades. To date, the principle mechanisms of its action include impeding tumoral angiogenesis and modulation of hosts’ immune system, affecting directly tumor cells, their progenitors, and neighboring stromal cells. Its better toxicity profile, lower cost, and easier use are main advantages over conventional therapies. The

APA, Harvard, Vancouver, ISO, and other styles

23

Spiliopoulou, Pavlina, Samantha Hinsley, Iain A. McNeish, Patricia Roxburgh, and Ros Glasspool. "Metronomic oral cyclophosphamide in relapsed ovarian cancer." International Journal of Gynecologic Cancer 31, no. 7 (2021): 1037–44. http://dx.doi.org/10.1136/ijgc-2021-002467.

Full text

Abstract:

ObjectivesTo describe the clinical activity of metronomic cyclophosphamide in a population of patients with recurrent ovarian cancer, and to identify predictors of clinical response.MethodsWe retrospectively reviewed all patients treated at our institution with oral metronomic cyclophosphamide for relapsed ovarian cancer between January 2012 and December 2016. These were identified from electronic chemotherapy prescription records. The primary endpoint was response rate by combined Gynecologic Cancer InterGroup (GCIG) criteria. Data on patient demographics, previous therapies, platinum resista

APA, Harvard, Vancouver, ISO, and other styles

24

Pietras, Kristian, and Douglas Hanahan. "A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer." Journal of Clinical Oncology 23, no. 5 (2005): 939–52. http://dx.doi.org/10.1200/jco.2005.07.093.

Full text

Abstract:

Purpose A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of antiangiogenic therapies. Pericytes have been revealed as functionally important for tumor neovasculature, using kinase inhibitors targeting their platelet-derived growth factor receptors (PDGFRs). Additionally, vascular endothelial growth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against early- but not late-stage disease. Materials and Methods Seeking to improve efficacy against otherwise in

APA, Harvard, Vancouver, ISO, and other styles

25

Trefzer, T., S. Stoelting, A. Lemke, et al. "Different responses of circulating endothelial progenitor cells and VEGF-plasma concentrations to low-dose metronomic and conventional chemotherapy." Journal of Clinical Oncology 25, no. 18_suppl (2007): 14053. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14053.

Full text

Abstract:

14053 Background: Endothelial progenitor cells (EPCs) may participate in tumor angiogenesis by providing cellular supply. This is a study that compares the effects of two conventional combination chemotherapy schedules to low-dose metronomic trofosfamide (an oral derivate of cyclophosphamide), using the number of circulating EPCs and vascular endothelial growth factor (VEGF) plasma levels in cancer patients. Methods: We measured circulating EPC and VEGF levels in 24 patients that received conventional chemotherapy for either breast cancer in an adjuvant setting or malignant lymphoma, and in 18

APA, Harvard, Vancouver, ISO, and other styles

26

Ueno, Takayuki, Norikazu Masuda, Shunji Kamigaki, et al. "Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR." International Journal of Molecular Sciences 20, no. 4 (2019): 984. http://dx.doi.org/10.3390/ijms20040984.

Full text

Abstract:

Endocrine therapy is an essential component in the curative treatment of hormone receptor (HR)-positive breast cancer. To improve treatment efficacy, the addition of metronomic chemotherapy has been tested and shown to improve therapeutic effects. To better understand cellular reactions to metronomic chemoendocrine therapy, we studied autophagy-related markers, beclin 1 and LC3, and apoptosis-related markers, TUNEL and M30, in pre- and post-treatment cancer tissues from a multicenter neoadjuvant trial, JBCRG-07, in which oral cyclophosphamide plus letrozole were administered to postmenopausal

APA, Harvard, Vancouver, ISO, and other styles

27

Cai, Zheng, Lang Gao, Kai Hu, and Qi-Ming Wang. "Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF-kB signaling pathway." World Journal of Clinical Oncology 15, no. 7 (2024): 895–907. http://dx.doi.org/10.5306/wjco.v15.i7.895.

Full text

Abstract:

BACKGROUND Parthenolide (PTL), a sesquiterpene lactone derived from the medicinal herb Chrysanthemum parthenium, exhibits various biological effects by targeting NF-kB, STAT3, and other pathways. It has emerged as a promising adjunct therapy for multiple malignancies. AIM To evaluate the in vitro and in vivo effect of PTL on cyclophosphamide (CTX) metronomic chemotherapy. METHODS The cytotoxicity of PTL and CTX on Lewis lung cancer cells (LLC cells) was assessed by measuring cell activity and apoptosis. The anti-tumor efficiency was evaluated using a tumor xenograft mice model, and the surviva

APA, Harvard, Vancouver, ISO, and other styles

28

Marmorino, Federica, Chiara Cremolini, Fotios Loupakis, et al. "Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial." Journal of Clinical Oncology 31, no. 15_suppl (2013): e14577-e14577. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14577.

Full text

Abstract:

e14577 Background: The protracted exposure to low doses of cytotoxics according to metronomic schedules reported encouraging results in the treatment of different malignancies. In a recent trial from our group, the association of a single standard dose of CTX followed by metronomic UFT and CTX with celecoxib showed a very favourable safety profile and promising activity in a cohort of heavily pre-treated patients (pts) with gastrointestinal tumors (Allegrini, 2012). The aim of the present trial was to prospectively evaluate the activity of metronomic cape and CTX in a population of refractory

APA, Harvard, Vancouver, ISO, and other styles

29

Brandi, G., S. Fanello, F. Piscaglia, et al. "Metronomic capecitabine in advanced patients with hepatocellular carcinoma (HCC): Preliminary results." Journal of Clinical Oncology 25, no. 18_suppl (2007): 15163. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15163.

Full text

Abstract:

15163 Background: No standard therapies are available for HCC patients (pts) ineligible for curative treatments. HCC has a rich neovasculature and neoangiogenesis is a negative prognostic factor: a high density of microvessels and hyperexpression of VEGF correlates with an increased propensity for invasion and metastatization and with a decreased DFS after resection. High level of circulating endothelial progenitors cells (CEPc) are related with insurgence and progression of HCC. Phase II trials with antiangiogenic agents in monotherapy had a response rate lower than 10% but stable disease (SD

APA, Harvard, Vancouver, ISO, and other styles

30

Marin Rodigheri, Sabrina, and Andrigo Barboza De Nardi. "Metronomic chemotherapy in dogs and cats – a review." Clínica Veterinária XVIII, no. 105 (2013): 40–48. http://dx.doi.org/10.46958/rcv.2013.xviii.n.105.p.40-48.

Full text

Abstract:

Metronomic chemotherapy represents a recent therapeutic option in human and veterinary oncology. It is characterized by continuous use of antineoplastic drugs at doses lower than the maximum tolerated dose, which are administered preferably orally and in close and regular intervals. Tumor control is obtained by continuous exposure of cancer cells to the drugs, inhibition of tumor angiogenesis and alterations in tumor immunology. The advantages of the metronomic protocols include low toxicity, easier administration, low cost and lower rates of resistance to antineoplastic drugs. The aim of this

APA, Harvard, Vancouver, ISO, and other styles

31

Patil, Vijay M., Vanita Noronh, Amit Joshi, et al. "Metronomic palliative chemotherapy in maxillary sinus tumor." South Asian Journal of Cancer 05, no. 02 (2016): 056–58. http://dx.doi.org/10.4103/2278-330x.181626.

Full text

Abstract:

Abstract Background: Metronomic chemotherapy consisting of methotrexate and celecoxib recently has shown promising results in multiple studies in head and neck cancers. However, these studies have not included patients with maxillary sinus primaries. Hence, the role of palliative metronomic chemotherapy in patients with maxillary sinus carcinoma that is not amenable to radical therapy is unknown. Methods: This was a retrospective analysis of carcinoma maxillary sinus patients who received palliative metronomic chemotherapy between August 2011 and August 2014. The demographic details, symptomat

APA, Harvard, Vancouver, ISO, and other styles

32

Kumar, M. N. V. Ravi, and Anil K. Sood. "Editorial – Metronomic chemotherapy." Cancer Letters 400 (August 2017): 203. http://dx.doi.org/10.1016/j.canlet.2017.03.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sarmiento, Roberta, and Giampietro Gasparini. "Antiangiogenic Metronomic Chemotherapy." Onkologie 31, no. 4 (2008): 161–62. http://dx.doi.org/10.1159/000119925.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Mpekris, Fotios, James W. Baish, Triantafyllos Stylianopoulos, and Rakesh K. Jain. "Role of vascular normalization in benefit from metronomic chemotherapy." Proceedings of the National Academy of Sciences 114, no. 8 (2017): 1994–99. http://dx.doi.org/10.1073/pnas.1700340114.

Full text

Abstract:

Metronomic dosing of chemotherapy—defined as frequent administration at lower doses—has been shown to be more efficacious than maximum tolerated dose treatment in preclinical studies, and is currently being tested in the clinic. Although multiple mechanisms of benefit from metronomic chemotherapy have been proposed, how these mechanisms are related to one another and which one is dominant for a given tumor–drug combination is not known. To this end, we have developed a mathematical model that incorporates various proposed mechanisms, and report here that improved function of tumor vessels is a

APA, Harvard, Vancouver, ISO, and other styles

35

Wu, Jiaming, Yu Dong, Wanshan Zhu, et al. "Capecitabine metronomic chemotherapy for metastatic colorectal cancer patients reaching NED: A protocol for a prospective, randomized, controlled trial." PLOS One 20, no. 4 (2025): e0320591. https://doi.org/10.1371/journal.pone.0320591.

Full text

Abstract:

Introduction An increasing number of patients with metastatic colorectal cancer (mCRC) have achieved no evidence of diseases (NED) status after surgery or other treatments. However, the latest guidelines for colorectal cancer do not recommend an appropriate treatment for patients with mCRC who achieve NED status. Capecitabine metronomic chemotherapy has the advantages of significant efficacy and minimal adverse reactions, it is a potential effective method for maintenance treatment for mCRC, but no RCTs have been reported. Therefore, we designed a randomized controlled trial to evaluate the ef

APA, Harvard, Vancouver, ISO, and other styles

36

Hara, Tomohiko, Satoru Yoshihiro, Hideaki Ito, et al. "Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer." Clinical medicine. Oncology 1 (January 2007): CMO.S304. http://dx.doi.org/10.4137/cmo.s304.

Full text

Abstract:

Background Metronomic chemotherapy is aimed at lessening the adverse effects of treatment while rendering cancer cells cytostatic. The oral 5-fluorouracil prodrug “5′-DFUR” has been shown to inhibit angiogenesis and is regarded as a good candidate agent for metronomic chemotherapy. Moreover, cisplatin and 5′-DFUR have been shown to synergistic cytotoxic effects. Methods We evaluated the safety and efficacy of metronomic chemotherapy using daily oral 5′-DFUR at the dose of 600 mg/day and biweekly cisplatin infusion at the dose of 20 mg/person in 23 patients with urothelial cancer resistant to c

APA, Harvard, Vancouver, ISO, and other styles

37

Clarke, Jennifer L., Fabio M. Iwamoto, Joohee Sul, et al. "Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma." Journal of Clinical Oncology 27, no. 23 (2009): 3861–67. http://dx.doi.org/10.1200/jco.2008.20.7944.

Full text

Abstract:

Purpose Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM. Patients and Methods Adult patients with newly diagnosed GBM were randomly assigned to receive standard radiotherapy with concurrent daily temozolomide followed by six adjuvant cycles of either dose-dense (150 mg/m2 days 1 to

APA, Harvard, Vancouver, ISO, and other styles

38

Yeh, Tsung-Jang, Leong-Perng Chan, Hui-Ting Tsai, et al. "The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience." Biology 10, no. 2 (2021): 168. http://dx.doi.org/10.3390/biology10020168.

Full text

Abstract:

Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aimed to demonstrate the outcomes of metronomic chemotherapy with tegafur–uracil in locally advanced head and neck squamous cell carcinoma (LA HNSCC). This was a retrospective study including 240 patients with LA HNSCC. After standard treatment, 96 patients were further treated with metronomic tegafur-uracil, and 144 patients were not. No statistical differences were found between both groups with regard to sex, clinical stage, or primary treatment choice. There were more hypopharyn

APA, Harvard, Vancouver, ISO, and other styles

39

Panthi, Vijay Kumar, Kamal Dua, Sachin Kumar Singh, Gaurav Gupta, Philip M. Hansbro, and Keshav Raj Paudel. "Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives." Pharmaceutics 15, no. 4 (2023): 1192. http://dx.doi.org/10.3390/pharmaceutics15041192.

Full text

Abstract:

Cancer-related death is a significant health and economic burden worldwide, and some conventional chemotherapy is associated with limited effectiveness in completely curing various cancers, severe adverse effects, and destruction of healthy cells. To overcome the complications associated with conventional treatment, metronomic chemotherapy (MCT) is extensively suggested. In this review, we aim to highlight the importance of MCT over conventional chemotherapeutic approach with emphasis on nanoformulations-based MCT, their mechanism, challenges, recent advances, and future perspectives. Nanoform

APA, Harvard, Vancouver, ISO, and other styles

40

Abdelmaksoud, Bader A., Mostafa M. Toam, and Alaa A. Fayed. "Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer." Breast Cancer Management 8, no. 3 (2019): BMT30. http://dx.doi.org/10.2217/bmt-2019-0012.

Full text

Abstract:

Aim: To evaluate the efficacy and safety of combined metronomic capecitabine with aromatase inhibitors (AIs) for patients with newly diagnosed metastatic hormone-receptor positive, HER2-negative breast cancer. Patients & methods: A total of 41 women with a diagnosis of metastatic hormone-receptor positive, HER2-negative breast cancer received oral metronomic capecitabine, 500 mg/m2 twice daily combined with an AI. Results: After a median follow-up of 24 months (9–50), a median of 15 months of treatment were completed, the median time to progression was 15 months (12.6–17.3) and the median

APA, Harvard, Vancouver, ISO, and other styles

41

Shaked, Yuval, Urban Emmenegger, Shan Man, et al. "Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity." Blood 106, no. 9 (2005): 3058–61. http://dx.doi.org/10.1182/blood-2005-04-1422.

Full text

Abstract:

Abstract Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term in this way with targeted therapies can be compromised by the empiricism associated with determining the optimum biologic dose (OBD). Using 4 distinct metronomic chemotherapy regimens in 4 different preclinical tumor models, including a hematologic malignancy, we established the OBD by determining the maximum efficacy associ

APA, Harvard, Vancouver, ISO, and other styles

42

Sysoev, A. E., L. I. Papusha, E. A. Salnikova, et al. "The effectiveness of stereotactic irradiation followed by metronomic MEMMAT therapy in children with oligometastatic recurrent medulloblastoma." Pediatric Hematology/Oncology and Immunopathology 22, no. 4 (2023): 108–13. http://dx.doi.org/10.24287/1726-1708-2023-22-4-108-113.

Full text

Abstract:

Low survival rates in children with recurrent medulloblastoma (MB) necessitate the search for new therapeutic approaches as alternatives to the existing treatment standards. Favorable dosimetric characteristics of stereotactic radiation techniques justify the use of such treatments for local radiation control in children with oligometastatic recurrent MB. Given the constant risk of metastatic dissemination and in order to potentiate response to radiation therapy and improve progression-free survival, metronomic molecular-targeted antiangiogenic therapy (MEMMAT, Medulloblastoma European Multita

APA, Harvard, Vancouver, ISO, and other styles

43

Kweon, Seho, Yoo-Seong Jeong, Yoon Gun Ko, et al. "Abstract 2730: Metronomic dose-finding approach of oral chemotherapy by experimentally-driven integrated mathematical modeling." Cancer Research 82, no. 12_Supplement (2022): 2730. http://dx.doi.org/10.1158/1538-7445.am2022-2730.

Full text

Abstract:

Abstract Conventional chemotherapy with maximum tolerated dose (MTD) has shown confident anti-cancer effect and when combined with targeted therapy, immunotherapy. Yet, understanding about how the MTD regimen is optimized has lacked due to its high tumor burdens. In this study, the oral doxorubicin (DOX) formulation was shown to improve oral bioavailability by 12.1% and sustain the metronomic concentration through the flexible protocol. Since the optimizing dose and schedules of DOX in metronomic chemotherapy (MCT) is essential to maximize efficacy and minimize toxicity, which is determined by

APA, Harvard, Vancouver, ISO, and other styles

44

Pandey, Avinash, A. Desai, V. Ostwal, et al. "Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India." South Asian Journal of Cancer 05, no. 02 (2016): 052–55. http://dx.doi.org/10.4103/2278-330x.181625.

Full text

Abstract:

Abstract Background: Oral cavity cancer is the most common cancer among rural India. There is a paucity of data for outcomes of operable oral cavity cancer from rural India. Use of maintenance metronomic may delay or avoid relapse. Aim: To evaluate outcomes of operable oral cavity carcinoma and evaluate impact of maintenance metronomic chemotherapy. Objectives: To evaluate disease-free survival (DFS), overall survival (OS), and factors affecting the outcome in operable oral cavity cancer. Materials and Methods: Data of patients diagnosed with oral cavity cancer registered between May 2008 and

APA, Harvard, Vancouver, ISO, and other styles

45

Carcamo, Benjamin, and Giulio Francia. "Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature." Journal of Clinical Medicine 11, no. 10 (2022): 2849. http://dx.doi.org/10.3390/jcm11102849.

Full text

Abstract:

We report a retrospective case series of six Hispanic children with tumors treated with metronomic chemotherapy. The six cases comprised one rhabdoid tumor of the kidney, one ependymoma, two medulloblastomas, one neuroblastoma, and a type II neurocytoma of the spine. Treatment included oral cyclophosphamide daily for 21 days alternating with oral etoposide daily for 21 days in a backbone of daily valproic acid and celecoxib. In one case, celecoxib was substituted with sulindac. Of the six patients, three showed complete responses, and all patients showed some response to metronomic therapy wit

APA, Harvard, Vancouver, ISO, and other styles

46

Mazánková, Dana, Veronika Bárková, and Pavel Mazánek. "Metronomická terapie v léčbě nádorových onemocnění." Česká a slovenská farmacie 71, no. 3 (2022): 91–97. http://dx.doi.org/10.5817/csf2022-3-91.

Full text

Abstract:

Metronomic therapy is a therapeutic method in selected oncological diseases, using long-term administration of low doses of drugs with direct or indirect antitumor effect. In addition, to direct cytotoxic eradication of tumor cells, metronomic therapy can very strongly affect the tumor microenvironment; it also has an immunomodulatory and antiangiogenic effect. Its minimal toxic profile allows for use in patients with severe organ dysfunctions and directly impacts the quality of life and social inclusion of oncological patients.

APA, Harvard, Vancouver, ISO, and other styles

47

Bilir, C., S. Durak, B. Kızılkaya, I. Hacıbekiroglu, E. Nayır, and H. Engin. "Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status." Current Oncology 24, no. 3 (2017): 199. http://dx.doi.org/10.3747/co.24.3486.

Full text

Abstract:

Background Metronomic chemotherapy—administration of low-dose chemotherapy—allows for a prolonged treatment duration and minimizes toxicity for unfit patients diagnosed with advanced non-small-cell lung cancer (nsclc).Methods Oral metronomic vinorelbine at 30 mg thrice weekly was given to 35 chemotherapy-naive patients who were elderly and vulnerable to toxicity and who had been diagnosed with advanced nsclc.Results Median age in this male-predominant cohort (29:6) was 76 years (range: 65–86 years). Histology was squamous cell carcinoma in 21 patients and adenocarcinoma in 14. There were no co

APA, Harvard, Vancouver, ISO, and other styles

48

Elsebaie, Hala, Wael Samir Makar Yassa, Shaimaa Lasheen, and Noha IbrahimIbrahim. "Efficacy, Safety and Cost Effectiveness of Metronomic Low Dose Versus Intermittent High Dose Capecitabine in Metastatic Breast Cancer." Open Access Macedonian Journal of Medical Sciences 9, B (2021): 1048–53. http://dx.doi.org/10.3889/oamjms.2021.7089.

Full text

Abstract:

AIM: The aim of the study is to compare the toxicity and cost-effectiveness between metronomic and intermittent capecitabine as maintenance therapy in female patients with metastatic breast cancer. PATIENTS AND METHODS: All metastatic breast cancer patients with HER2 negative were included. The whole study population received six cycles of Docetaxel/Capecitabine then patients were randomized to either continuous (650 mg/m2 twice daily continuous) or intermittent Capecitabine (1000 mg/m2 twice daily every 21 days) as maintenance. RESULTS: The study included 51 patients, 26 in the metronomic arm

APA, Harvard, Vancouver, ISO, and other styles

49

André, Nicolas, Manon Carré, and Eddy Pasquier. "Metronomics: towards personalized chemotherapy?" Nature Reviews Clinical Oncology 11, no. 7 (2014): 413–31. http://dx.doi.org/10.1038/nrclinonc.2014.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Laquente, B., C. Lacasa, M. Morell, et al. "Antitumoral effect of gemcitabine metronomic schedule in a xenograft pancreatic model." Journal of Clinical Oncology 24, no. 18_suppl (2006): 12031. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.12031.

Full text

Abstract:

12031 Background: Human tumor xenografts in mice can be remarkably predictive of response in humans to cytotoxic chemotherapeutic drugs. Tumor endothelial cells are sensitive to the action of conventional cytotoxic drugs when they are regularly administrated at low doses. This concept, known as metronomic chemotherapy, has been demonstrated in preclinical studies using transplanted tumor models. We aim to investigate the potential anti-tumoral activity of Gemcitabine (G) when administered in a low-dose schedule in an ortothopic implantation model of human pancreatic carcinomas. Methods: Standa

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!